176 related articles for article (PubMed ID: 26197808)
21. Lithium, a potential protective drug in Alzheimer's disease.
Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
Chatterjee P; Roy D; Rathi N
J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
[TBL] [Abstract][Full Text] [Related]
23. Analysis of network based co-expression modules for Alzheimer's disease.
Dua P; Bais S; Lukiw WJ
Stud Health Technol Inform; 2013; 192():1227. PubMed ID: 23921001
[TBL] [Abstract][Full Text] [Related]
24. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.
Issa NT; Kruger J; Wathieu H; Raja R; Byers SW; Dakshanamurthy S
BMC Bioinformatics; 2016 May; 17(1):202. PubMed ID: 27151405
[TBL] [Abstract][Full Text] [Related]
25. Human Pathway-Based Disease Network.
Yu L; Gao L
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(4):1240-1249. PubMed ID: 29990107
[TBL] [Abstract][Full Text] [Related]
26. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis.
Toro-Domínguez D; Carmona-Sáez P; Alarcón-Riquelme ME
Arthritis Res Ther; 2017 Mar; 19(1):54. PubMed ID: 28284231
[TBL] [Abstract][Full Text] [Related]
27. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
28. Computational Drug-repositioning Approach Identifying Sirolimus as a Potential Therapeutic Option for Inflammatory Dilated Cardiomyopathy.
Shibata K; Endo T; Kuribayashi Y
Drug Res (Stuttg); 2019 Oct; 69(10):565-571. PubMed ID: 31238376
[TBL] [Abstract][Full Text] [Related]
29. Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo.
Li J; Wang G; Liu J; Zhou L; Dong M; Wang R; Li X; Li X; Lin C; Niu Y
Eur J Pharmacol; 2010 Dec; 649(1-3):195-201. PubMed ID: 20868658
[TBL] [Abstract][Full Text] [Related]
30. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's Disease Drug Discovery--11th International Conference--Promising New Therapeutic Approaches. 27-28 September 2010, Jersey City, NJ, USA.
Wolfe MS
IDrugs; 2010 Dec; 13(12):825-7. PubMed ID: 21154134
[TBL] [Abstract][Full Text] [Related]
32. Integrative cancer pharmacogenomics to establish drug mechanism of action: drug repurposing.
El-Hachem N; Ba-Alawi W; Smith I; Mer AS; Haibe-Kains B
Pharmacogenomics; 2017 Nov; 18(16):1469-1472. PubMed ID: 29057710
[No Abstract] [Full Text] [Related]
33. Modeling Path Importance for Effective Alzheimer's Disease Drug Repurposing.
Xiang S; Lawrence PJ; Peng B; Chiang C; Kim D; Shen L; Ning X
Pac Symp Biocomput; 2024; 29():306-321. PubMed ID: 38160288
[TBL] [Abstract][Full Text] [Related]
34. Biocomputing drug repurposing toward targeted therapies.
Cardone L
Aging (Albany NY); 2016 Nov; 8(11):2609-2610. PubMed ID: 27920407
[No Abstract] [Full Text] [Related]
35. CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity.
Parsons CG
Neuropharmacology; 2019 Mar; 147():4-10. PubMed ID: 30165077
[TBL] [Abstract][Full Text] [Related]
36. Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.
Watamura N; Toba J; Yoshii A; Nikkuni M; Ohshima T
J Neurosci Res; 2016 Jan; 94(1):15-26. PubMed ID: 26400044
[TBL] [Abstract][Full Text] [Related]
37. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case.
Huang LC; Soysal E; Zheng W; Zhao Z; Xu H; Sun J
BMC Syst Biol; 2015; 9 Suppl 4(Suppl 4):S2. PubMed ID: 26100720
[TBL] [Abstract][Full Text] [Related]
38. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease.
Lee SY; Song MY; Kim D; Park C; Park DK; Kim DG; Yoo JS; Kim YH
Front Pharmacol; 2019; 10():1653. PubMed ID: 32063857
[TBL] [Abstract][Full Text] [Related]
39. Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms.
Giuliani D; Ottani A; Zaffe D; Galantucci M; Strinati F; Lodi R; Guarini S
Neurobiol Learn Mem; 2013 Sep; 104():82-91. PubMed ID: 23726868
[TBL] [Abstract][Full Text] [Related]
40. Insights into Computational Drug Repurposing for Neurodegenerative Disease.
Paranjpe MD; Taubes A; Sirota M
Trends Pharmacol Sci; 2019 Aug; 40(8):565-576. PubMed ID: 31326236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
